Summary
The company focuses on developing innovative genetic constructs that specifically target cancer cells, enabling them to self-identify and self-destruct. Their approach aims to revolutionize early cancer detection and treatment, making the experience of cancer less severe by catching it at its earliest stages. They collaborate with various partners to enhance their technology and have received significant funding to advance their mission.
Based on content on earli.com
No similar companies found
We offer API access to our data.
8 of 8 checks passed
Label
Value
Active Dates
12.2 years — Since Oct 2012
Web Hosting
Platform
E-Mail Provider
Microsoft Office 365
NAICS Code
541714
SIC 4 Digit Code
8731
SIC 2 Digit Code
87
Industry
1. Biotechnology and Healthcare
2. Research and Development in Biotechnology (except Nanobiotechnology)
Vendor
Source
Microsoft
TXT Record
TXT Record
IBM NS1
NS Record
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2012 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2013 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2014 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2015 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2016 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2017 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2018 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2019 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2020 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2021 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2022 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2023 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2024 |
|
|
|
|
|
|
|
|
|
|
|
|